Amphastar Pharmaceuticals (AMPH) Stock Forecast, Price & News

Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

Is Amphastar Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amphastar Pharmaceuticals stock.
View analyst ratings for Amphastar Pharmaceuticals or view top-rated stocks.

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Amphastar Pharmaceuticals.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its quarterly earnings results on Tuesday, May, 10th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.11. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 17.35% and a net margin of 17.87%. During the same quarter in the previous year, the business posted $0.27 earnings per share.
View Amphastar Pharmaceuticals' earnings history.

What price target have analysts set for AMPH?

3 equities research analysts have issued 1-year price objectives for Amphastar Pharmaceuticals' shares. Their forecasts range from $32.00 to $43.00. On average, they anticipate Amphastar Pharmaceuticals' stock price to reach $36.67 in the next year. This suggests a possible upside of 8.0% from the stock's current price.
View analysts' price targets for Amphastar Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the following people:

• Dr. Ziping Luo Ph.D., Chairman, Chief Scientist & COO (Age 72, Pay $1.34M)
• Dr. Yongfeng Zhang Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 75, Pay $1.93M)
• Mr. William J. Peters M.B.A., CFO, Exec. VP of Fin. & Treasurer (Age 54, Pay $1.11M) (LinkedIn Profile)
• Mr. Jacob Liawatidewi M.B.A., Exec. VP of Sales, Marketing & Corp. Admin. Center and Corp. Sec. (Age 48, Pay $773.69k)
• Mr. Rong Zhou M.S., Exec. VP of Production Center (Age 63, Pay $842.77k) (LinkedIn Profile)
• Dan Dischner, VP of Corp. Communications
• Tony Marrs, Sr. VP of Regulatory Affairs and Clinical Operations
• Mr. Peter Langosh, VP of Operational Improvement and VP of Internal Audit (Age 69)

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among Amphastar Pharmaceuticals' employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amphastar Pharmaceuticals' key competitors?

Some companies that are related to Amphastar Pharmaceuticals include Sarepta Therapeutics (SRPT), Legend Biotech (LEGN), Intra-Cellular Therapies (ITCI), Ionis Pharmaceuticals (IONS), Acerus Pharmaceuticals (ASPCF), Perrigo (PRGO), Hypera (HYPMY), Ascendis Pharma A/S (ASND), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Evotec (EVTCY), Cerevel Therapeutics (CERE), Galapagos (GLPG), Arrowhead Pharmaceuticals (ARWR) and CureVac (CVAC).
View all of AMPH's competitors.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.55%), Federated Hermes Inc. (7.14%), Vanguard Group Inc. (5.09%), Dimensional Fund Advisors LP (3.68%), State Street Corp (2.71%) and Nantahala Capital Management LLC (0.00%). Company insiders that own Amphastar Pharmaceuticals stock include David Maris, Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends for Amphastar Pharmaceuticals.

Which institutional investors are selling Amphastar Pharmaceuticals stock?

AMPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Assenagon Asset Management S.A., Eagle Asset Management Inc., BlackRock Inc., SG Americas Securities LLC, Arrowstreet Capital Limited Partnership, and Nisa Investment Advisors LLC. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Floyd F Petersen, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, and Yakob Liawatidewi.
View insider buying and selling activity for Amphastar Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was bought by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, Hillsdale Investment Management Inc., Penserra Capital Management LLC, Friess Associates LLC, EAM Investors LLC, Calamos Advisors LLC, and Acadian Asset Management LLC.
View insider buying and selling activity for Amphastar Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $33.94.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals has a market capitalization of $1.66 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.61 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals employs 1,761 workers across the globe.

What is Amphastar Pharmaceuticals' official website?

The official website for Amphastar Pharmaceuticals is www.amphastar.com.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at (909) 980-9484, via email at [email protected], or via fax at 909-980-8296.